Found 2 bookmarks
Custom sorting
Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomized, double-blind, placebo-controlled trial
Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomized, double-blind, placebo-controlled trial

bovhyaluronidase azoximer improved exercise tolerance and reduced breathlessness in post-COVID-19 patients.

Faster lung recovery was noted in those with cardiovascular issues after 180 days.

#lung#lungs#pulmonary#bovhyaluronidase azoximer#long covid#treatment#Post-Acute Conditions
·medrxiv.org·
Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomized, double-blind, placebo-controlled trial
Diaphragm Muscle Atrophy Contributes to Low Physical Capacity in COVID-19 Survivors
Diaphragm Muscle Atrophy Contributes to Low Physical Capacity in COVID-19 Survivors

“We identified that 69.5% of patients had diaphragm atrophy and 6.5% had diaphragm paralysis…

…The percentage of atrophy was not related to age, gender, BMI, oxygen therapy usage during the COVID-19 infection course, and disease severity."

#diaphragm atrophy#diaphragm#diaphragm paralysis#lungs#pulmonary#breathing#Post-Acute Conditions
·mdpi.com·
Diaphragm Muscle Atrophy Contributes to Low Physical Capacity in COVID-19 Survivors